Follow the guidelines
XIFAXAN was given the highest possible recommendation by AASLD/EASL as an add-on therapy to lactulose for the reduction in risk of OHE recurrence2,*
XIFAXAN earned AASLD/EASL’s highest possible recommendation (GRADE I,A,1) as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a patient has a recurrence while on lactulose alone.2,*
I,A,1 is the highest possible recommendation.2
Explore an important recommendation from the AASLD Guidelines
Watch Dr. Jesudian discuss some of the AASLD Guidelines for reducing the risk of OHE recurrence with XIFAXAN.
What can you do to help reduce your patients’ risk of OHE recurrence?
*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is “high quality,” and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is “strong,” with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.2
OHE, overt hepatic encephalopathy
AASLD, American Association for the Study of Liver Diseases
EASL, European Association for the Study of the Liver
HE, hepatic encephalopathy
INDICATIONS
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
